PHARMACEUTICAL INDUSTRY OPPOSITION
'We're no longer paying...': Trump sets deadline for pharma firms to lower US prescription drug costs in new order
Donald Trump signed an order to cut drug costs. Pharma companies have 30 days to comply. Otherwise, the government will limit payments. The order directs the health department to negotiate prices. US drug prices will be linked to lower costs in other countries. Trump claims this will save taxpayers trillions. He accuses other countries of exploiting America.
Trump announces 59% drug prices cut
Donald Trump plans to cut drug prices by 59 percent. He announced this after unveiling a new pharmaceutical policy. Trump aims to sign an executive order to reduce prices. The order would implement a "most favored nation's" policy. This would link US drug costs to the lowest prices paid by other countries. He tried similar plans before, but faced opposition.
Trump promises to order that the US pay only the price other nations do for some drugs
Donald Trump announced he will sign an executive order aiming to lower drug costs by tying Medicare prices for certain medications administered in doctor's offices to the lowest prices paid by other countries. This "most favored nation" policy, targeting drugs covered under Medicare Part B, seeks to address the disparity in U.S. drug prices compared to other nations.
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of more than 49% in 1 year
The way the street has reacted to early Q4 results, it appears that the market has priced in some of the numbers. So, it is probably time to be bullish, but also very selective. There is, however, a caveat. Global developments can still play spoilsport and cause the market to come under pressure. Our selected stocks for today depict a strong upward trajectory in their overall average score which is based on five key pillars: Earnings, fundamentals, relative valuation, risk, and price momentum. This implies that there has been a significant improvement in their market outlook in the given time frame.
India finds a place in EU's expanding €2 trillion trade playbook as bloc's ties with US sour
Facing escalating trade tensions with the US under President Trump, the European Union is actively pursuing trade diversification by forging new agreements with countries worldwide. While lobbying for tariff reductions in Washington, the EU is accelerating trade talks with nations in Asia and South America, aiming to offset potential losses from strained transatlantic relations.
Too early to deploy cash, stay domestic-focused amid market uncertainty: Mihir Vora
Mihir Vora, CIO of Trust Mutual Fund, discusses a cautious but optimistic outlook on domestic stocks, with a focus on banks, large NBFCs, and domestic cyclicals. He highlights the potential positive impacts of a US-induced crisis, such as reduced interest rates and commodity prices.
- Go To Page 1
Rahul Gandhi slams US tariffs, Govt's silence on China
Rahul Gandhi, during Zero Hour in the Lok Sabha, warned that US President Trump’s proposed 26-27% reciprocal tariffs will severely impact India's economy, encompassing the auto, pharmaceutical, and agricultural sectors. Gandhi also demanded clarity on the government’s position regarding China's reported occupation of 4,000 square kilometers of Indian territory.
Australia says US tariffs 'not act of a friend' but rules out reciprocal move
U.S. President Donald Trump's decision to impose a 10% tariff on Australian goods has been criticized by Australian Prime Minister Anthony Albanese, calling it "not the act of a friend." Despite the tariffs, Australia ruled out reciprocal duties to avoid higher prices for households.
Tariffs imposed by US will 'completely devastate' Indian economy: Rahul Gandhi
Rahul Gandhi claims China has taken over 4,000 sq km of Indian territory and criticizes the Indian government's lack of response. He also warns that US tariffs will devastate the Indian economy, emphasizing the need for the government to address these crucial issues.
Specialty chemicals: Stick to few as a mix of head and tailwinds emerges. 5 stocks with upside potential of up to 40%
As the tariff war gets hotter, a good bit of the heat will be generated in the specialty chemicals space. Why? Because, chemical supply chains are very rigid by nature. To put this in perspective: If a product uses a certain chemical as raw material, and if there is a sudden shortage of that chemical, can it be replaced by another one? The answer is no. For the user, there is no option but to buy that chemical at a higher cost. Now, the reverse scenario. Suppose there is sudden overproduction of the chemical, will the user buy more because it is cheaper? The answer is again no. So, as tariffs cause disruption in the chemicals sector, we will see a mix of head and tailwinds.
This ratio will gain importance in the coming months. 5 stocks which fit with bill with an upside potential of up to 42%
There is always the chance of going wrong in the market. So, caution and a long-term perspective should be your mantras. But there are times like now (an economic slowdown coupled with global issues) when thinking before deciding is a must. This is also when value becomes important. Now, most investors ascertain value using the price-to-earning or PE ratio. But, as the market adjusts to the Q3 numbers and prices in Q4, relying on this ratio could lead to more wrong decisions than right. When looking at a long-term investment, it is better to use the lesser-known PEG ratio. It helps you avoid stocks which might appear cheap but actually are not value buys. Again, in sectors that are cyclical in nature, looking at the PE matrix alone may lead to wrong decisions.
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analysts
In a week that saw volatility in the Nifty and Sensex, and the US and other global markets were also trading with cuts on most days, sentiment was bound to turn bearish. And it will only get worse, what with more and more people throwing the word “recession” around. Will this continue for some more time? Yes, surely; and why not? In a world where tariffs on whisky are making headlines, probably the market can and may get a bit more tipsy. So, time to look beyond the next four years of Trump’s tenure? Just remember: The market has endured many such four-year stints.
These mid-cap stocks with ‘strong buy’ & ‘buy’ recos can rally over 28%, according to analysts
From being the most loved segment of the market, mid-caps are today under fire from all sides. Switch on a business channel and you will hear 10 reasons why mid-caps are under pressure. And why they are likely to continue facing the music. The fact is that, if there is a recovery for three consecutive days, you will hear exactly the opposite of what is being said today. This is not to say that valuations in the mid-cap segment were not high and required a correction. But it is time to look at each stock and business separately and think medium- to long-term rather than wondering what is going to happen to the Nifty on an every-day basis.
The United States drug industry used to oppose patents - what changed?
Drugmakers quickly voiced their opposition to the move, but public health advocates were elated. Waiving patent rights, the thinking goes, will give poorer countries the ability to procure low-cost generic versions of COVID-19 vaccines, even if they are produced in another country, and help them to more effectively fight a public health crisis. The European Parliament now supports the idea as well.
Another gas leakage at Vizag factory kills two, critically injures four
Uday Kumar, Inspector, Parwada Police Station said that the situation is under control now. "Two people dead and four are admitted at hospitals. The situation is under control now. The two persons who died were workers and were present at the leakage site. Gas has not spread anywhere else," said Uday Kumar.
India's plan to reduce medicine prices faces industry pushback
The Draft Pharmaceutical Policy has made no progress since opposition emerged from the industry and among some government agencies.
Indian investments in Venezuela face no threat: Venezuelan Ambassador to India Augusto Montiel
The opposition leadership, in cooperation with external powers in the region and the OAS, have recklessly called for increased violence and death, he said.
Indian drug control weakest in the world, need to bolster it: Subburaj, Pharma Secretary
Subburaj acknowledged that the industry is saddled with many issues and departments work at cross-purposes on key matters.
Soon, you may get vegetarian capsules
As of now the Bureau of Indian Standards has already framed standards, norms and guidelines for manufacturing vegetarian capsules based on cellulose.
Government exempts barcoding plan for primary packaging of medicines
Adopting sophisticated technologies to print unique product identification code on primary packaging involved huge and unwarranted capital expenditure.
Decisive victory on FDI in retail in Rajya Sabha: Anand Sharma
Commerce and Industry Minister Anand Sharma said government achieved a "decisive victory" on FDI and alleged BJP is adopting "double standard".
Patents appeal board rejects AstraZeneca's plea on cancer drug
Patents appeal board has dismissed AstraZeneca's petition challenging an earlier ruling that refused patent protection for a cancer-fighting drug.
National Pharma Pricing Policy may hurt industry in long-run
Pharma analysts in India and abroad believe that cost-based pricing in National Pharmaceutical Pricing Policy is not suitable to safeguard the interests of patients.
FIPB to vet pharma FDI as Competition Commission of India needs time
The government is grappling with regulating stake acquisition of 74% or more by foreign pharmaceutical firms in local drug companies.
Pharmaceuticals department may link drug prices with government procurement rates
DoP is considering linking mkt prices of medicines to rates at which govt procures generic drugs in bulk for its hospitals and health programmes.
Sun rejects Guggenheim’s $215 mn offer for Taro stake
Guggenheim Partners offered to buy Sun Pharmaceutical Industries’ stake in Taro Pharmaceuticals Industries on behalf of clients for about $215 million.
Govt for discussion on FDI in multi-brand retail
India on Monday said it would next month initiate discussion on liberalising Foreign Direct Investment in sectors ranging from defence to agriculture and even retail -- a source of political woes for the government in the past.
China told to pull up cos selling fake ‘made-in-India’ drugs in Nigeria
India has asked China to take ”strict” action against Chinese companies selling fake drugs in Nigeria with ‘made-in-India’ labels, said an official in the government.
Local pharma strikes first in patent war
Global innovator pharma companies and domestic generic players are sparring with each other in the wake of India’s new product patent regime.
Load More
